Rossmore Private Capital boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 1.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 58,112 shares of the company’s stock after purchasing an additional 645 shares during the quarter. Johnson & Johnson accounts for about 2.9% of Rossmore Private Capital’s portfolio, making the stock its 5th largest holding. Rossmore Private Capital’s holdings in Johnson & Johnson were worth $8,094,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. Fisher Asset Management LLC increased its holdings in Johnson & Johnson by 2.6% in the 2nd quarter. Fisher Asset Management LLC now owns 11,841,121 shares of the company’s stock valued at $1,649,231,000 after buying an additional 301,124 shares during the period. Clearbridge Investments LLC increased its holdings in Johnson & Johnson by 0.5% in the 1st quarter. Clearbridge Investments LLC now owns 9,628,443 shares of the company’s stock valued at $1,345,960,000 after buying an additional 48,582 shares during the period. Nordea Investment Management AB increased its holdings in Johnson & Johnson by 14.2% in the 1st quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock valued at $1,217,494,000 after buying an additional 1,079,751 shares during the period. Thoroughbred Financial Services LLC increased its holdings in Johnson & Johnson by 14,147.0% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock valued at $401,425,000 after buying an additional 3,986,071 shares during the period. Finally, Swedbank increased its holdings in Johnson & Johnson by 5.5% in the 4th quarter. Swedbank now owns 4,001,754 shares of the company’s stock valued at $509,303,000 after buying an additional 209,665 shares during the period. Institutional investors and hedge funds own 67.23% of the company’s stock.
Shares of Johnson & Johnson stock traded down $1.02 during midday trading on Wednesday, hitting $128.62. 30,426 shares of the company traded hands, compared to its average volume of 7,262,639. The stock has a market cap of $337.10 billion, a price-to-earnings ratio of 15.72, a PEG ratio of 2.16 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33. The firm’s fifty day moving average price is $131.66 and its 200-day moving average price is $136.44. Johnson & Johnson has a 12 month low of $121.00 and a 12 month high of $148.99.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 2.95%. The ex-dividend date is Monday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.
In other Johnson & Johnson news, Director Marillyn A. Hewson bought 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The shares were acquired at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the transaction, the director now directly owns 3,000 shares in the company, valued at $419,040. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.23% of the stock is owned by company insiders.
Several equities analysts have commented on the stock. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price on the stock. in a report on Thursday, July 18th. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Bank of America reaffirmed a “hold” rating and set a $150.00 price target on shares of Johnson & Johnson in a report on Tuesday, July 16th. Raymond James decreased their price target on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a report on Wednesday, July 17th. Finally, Barclays initiated coverage on shares of Johnson & Johnson in a report on Friday, June 21st. They set a “hold” rating and a $140.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $150.60.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: Momentum Investing
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.